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AbstrAct:
Recent developments in multi-functional nanoparticles offer a great potential for 
targeted delivery of therapeutic compounds and imaging contrast agents to specific 
cell types, in turn, enhancing therapeutic effect and minimizing side effects. Despite 
the promise, site specific delivery carriers have not been translated into clinical 
reality. In this study, we have developed long circulating liposomes with the outer 
surface decorated with thioated oligonucleotide aptamer (thioaptamer) against 
E-selectin  (ESTA)  and  evaluated  the  targeting  efficacy  and  PK  parameters.  In 
vitro targeting studies using Human Umbilical Cord Vein Endothelial Cell (HUVEC) 
demonstrated efficient and rapid uptake of the ESTA conjugated liposomes (ESTA-
lip). In vivo, the intravenous administration of ESTA-lip resulted in their accumulation 
at  the  tumor  vasculature  of  breast  tumor  xenografts  without  shortening  the 
circulation  half-life.  The  study  presented  here  represents  an  exemplary  use  of 
thioaptamer for targeting and opens the door to testing various combinations of 
thioaptamer  and  nanocarriers  that  can  be  constructed  to  target  multiple  cancer 
types and tumor components for delivery of both therapeutics and imaging agents.
INtrOdUctION
Treatment for solid tumors has largely relied on 
initial surgical intervention and subsequent scheduled 
cytotoxic chemotherapies. However, the vast majority 
of malignancies have proven to be resistant to these 
approaches, partially due to the requisite dose limitations 
for preventing adverse effects on normal tissues. Recent 
advances  in multi-functional drug delivery systems 
provide insight into development of nanoscale carriers for 
cancer treatment and imaging [1-3]. Current nanoscale 
delivery systems that are approved by FDA rely on passive 
targeting through leaky vessels, which is a hallmark 
of tumor vasculature [4, 5]. This class of nanoparticles 
improves the solubility, toxicity profile, and unfavorable 
pharmacokinetics of the chemotherapeutics. However, 
the  therapeutic  efficacy  remains  largely  unchanged  [6, 
7]. Therefore, development of a tool to allow for constant 
and selective delivery of therapeutics is desirable. Active 
targeting  can  be  achieved  by  efficient  recognition  of 
tumor specific antigens that are differentially expressed 
cell surface proteins between normal and tumor. An 
affinity-based  interaction  between  the  antigens  and 
targeted ligand increase delivery efficacy by enhancing Oncotarget 2011; 2:  298 - 304 299 www.impactjournals.com/oncotarget
the retention of nanoparticles and elevating cellular uptake 
while minimizing side effects associated with potential 
off-targeting [1]. 
Among tumor components, tumor vasculature is 
an attractive target for the delivery of anti-cancer and 
imaging contrast agents. The concept of tumor vasculature 
targeting is substantially distinct from targeting cancer 
cells [1, 8]. When nanoparticles are administered 
intravenously to target cancer cells, they are required 
to physically cross over the layers of endothelial lining 
against oncotic pressure that is generated from inside the 
tumor microenvironment. In contrast, for vasculature 
targeted nanoparticles, the intended molecular targets 
on the endothelial cell surface are readily accessible to 
the circulating nanoparticles. Tumor vasculature is in 
an  inflamed  state  and  overexpresses  several  important 
factors such as adhesion molecules [9, 10]. E-selectin 
(CD62E,  ELAM-1  or  LECAM-2)  is  selectively 
expressed  in  inflamed  vasculature  in  advanced  tumors 
by cytokines that are secreted in the inflammatory tumor 
microenvironment [11-13]. The inducible nature of 
E-selectin in the inflammatory environment would allow 
for site specific delivery of nanoparticle to the inflamed 
tumor vasculature and possibly to tumor parenchyma 
via  subsequent  extravasation.  We  recently  identified 
a  thiophosphate-backbone  modified  oligonucleotide 
aptamer  (“thio”aptamer)  that  binds  E-selectin 
expressed  on  endothelial  cells  with  high  affinity  and 
specificity [14]. In this study, we developed E-selectin 
thioaptamer conjugated stealth liposomes and analyzed 
physico-chemical  properties,  targeting  efficiency,  and 
pharmacokinetics. We herein report on 1) application of 
thioated aptamer for drug delivery, 2) tumor vasculature 
targeting,  and  3)  the  effect  of  aptamer  conjugation  on 
pharmacokinetics of stealth liposomes.
rEsULts
development of EstA conjugated liposomes
We  first  developed  ESTA  conjugated  liposome 
(ESTA-lip)  for  effective  vasculature  targeting.  The 
efficiency  of  conjugation  was  evaluated  by  coupling 
Cy3 labeled carboxylated ESTA (COOH-Cy3-ESTA) on 
amino  PEGylated  stealth  liposome  (NH2-PEG-lip)  (A) 
and  the  intensity  of  red  fluorescence  was  measured  at 
anexcitation/ emission of 544/594 nm using a fluorimeter. 
A linear standard curve was generated from Cy3-labeled 
ESTA. Approximately 50% of the surface amino groups 
presenton  the  liposome  were  conjugated  to  the  ESTA 
(~485 ESTA molecules conjugated to one liposome) (Fig. 
1B). The physico-chemical properties of the liposomes 
wereanalyzed by a zeta-sizer and Fourier Transform 
InfraRed  spectroscopy  (FTIR). The  size  of  NH2-PEG-
lip  was  110.2nm  in  average,  and  ESTA  conjugation 
caused a slight increase of size of the liposomes (119.3 
nm)  (Fig.  1C).  The  analysis  of  zeta-potential  showed 
that ESTA conjugation resulted in a substantial change 
of the surface charge of the NH2-PEG lip from +5.5 ± 
1.7 mV to -5.6 ± 2.8 mV (Fig. 1C). This indicated that 
the positive charge of the amino groups on the liposome 
surface was substituted by the negatively charged ESTA. 
Figure 1: Physico-chemical properties of EstA conjugated liposomes. (A) Scheme of TA conjugation to liposome. (B) Quantification 
of ESTA conjugation on the liposomes. Fluorescence intensity of Cy3-labeled ESTA was plotted against ESTA concentration. Using the 
standard curve the number of ESTA molecules on ESTA-lip was estimated based on fluorescence measurement. (C) Size and charge of the 
liposomes. The size of the liposomes was measured using a dynamic light scattering (DLS) and the surface charge was measured by zeta 
potential. (D) FTIR spectrum of the non labeled-liposomes and ESTA-lips. 
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Figure 2: E-selectin dependent binding of EstA-lip on E-selectin expressing cells. (A) Induction of E-selectin expression on 
the HUVEC cells. HUVEC were stimulated with TNF-α (10ng/ml) for 4 hours. Cells were dissociated with 5mM EDTA and then incubated 
with FITC labeled E-selectin antibody. Surface fluorescence was measured by flow cytometry and averaged for three separate experiments.   
(B) ESTA-lip binding to the HUVEC expressing E-selectin. HUVEC was incubated with TNF-α (10ng/ml) for 3 hours to induce E-selectin 
expression. The cells were further incubated with Cy3-ESTA-lip-FITC (10 nM) for 2 hours. All images were captured at the same exposure 
condition for comparison. The final images shown are representative images (at the final magnification: x600) from five random fields of at 
least three independent experiments. Blue, Hoechst 33342; Red, ESTA; Green, FITC-lip. (C) Immunohistochemical analysis for E-selectin 
expression on the vasculature of mouse bearing breast xenograft tumor derived from MDA-MB-231. ESTA-lip-Rhodamine were intravenously 
injected and the tumor was dissected 5 hr after the injection and frozen sections were generated to identify the localization of the liposomes 
by using fluorescent microscope. (D) ESTA-lip accumulation in tumor parenchyma after 48 hr after the injection. Red, lip-Rhodamine; Blue, 
Hoechst 33342. 
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Additionally, the spectra acquired from FTIR analysis of 
the Cy3-ESTA-lip were compared to the NH2 PEG lip and 
ESTA (Fig. 1D). A reduction in peaks corresponding to 
C=O stretch (1650 cm-1) and C-O stretch (1230 cm-1) as 
compared to the non-reactive peak corresponding to P=O 
bending (1040 cm-1) was observed in ESTA-lip. The O-H 
bend in the COOH-ESTA (1480 cm-1) appeared slightly 
shifted and partially reactive due to the contribution of 
O-H from water. Taken together, these data demonstrated 
the successful conjugation of COOH-Cy3-ESTA to the 
NH2-PEG-lip.
Binding of ESTA-lip to inflamed endothelial cells
To  test  binding  efficiency  of  ESTA-lip  in vitro, 
HUVEC were stimulated with TNF-α to induce E-selectin 
expression on the cell membrane. TNF-α treatment 
increased  the  expression  of  E-selectin  more  than  20-
fold  when  compared  to  untreated  cells  (Fig.  2A).  The 
TNF-α treated cells were used to test the ability of the 
Cy3-ESTA-lip-FITC  (Cy3-ESTA  conjugated  liposome 
containing FITC) to bind to E-selectin on the HUVEC 
cell surface. The cells treated with Cy3-ESTA-lip-FITC 
at a concentration of 10 nM showed intense FITC and 
Cy3  fluorescence  in  the  cells  stimulated  with  TNF-α 
when  compared  with  un-stimulated  controls  (Fig.  2B).
The merged fluorescence of FITC and Cy3 suggest that 
the Cy3-ESTA-lip-FITC were internalized after binding 
to E-selectin on the cell surface. This co-migration of 
both thioaptamer and liposome was observed within 24 
hours (data not shown). Regardless of TNF stimuli, un-
conjugated liposomes as negative control only showed 
minor interaction to the cells and the fluorescent signal was 
almost undetectable after normalization (supplemental 
figure 1). To further examine selective binding of ESTA-
lip to E-selectin in vivo, ESTA-lip-Rhodamine was i.v. 
injected into mice bearing breast tumor xenografts (Figure 
2C). The expression level of E-selectin was upregulated on 
the tumor vasculature of xenograft tumors, predominantly 
expressed in or neighboring regions of tumor stroma 
(Fig. 2C, left). The mouse bearing tumors received an 
injection of ESTA-lip-Rhodamine via tail vain, and the 
mice  were  sacrificed  5  h  post-injection  to  harvest  the 
tumor and the major organs. Intravenous bolus injection 
of the ESTA-lip-Rhodamine (3 mg of liposome in 100 µl 
saline) resulted in an accumulation of red fluorescence 
on the tumor vasculature (Fig. 2C, right), while minimal 
level of fluorescence was detected around the vessel area 
when un-conjugated-lip was injected (data not shown). In 
contrast, ESTA conjugation did not affect accumulation 
of liposomes in the sinusoidal organs (data not shown). 
These  data  demonstrated  that  ESTA-lip  preferentially 
binds to E-selectin expressing human and mouse 
endothelial cells in vitro and in vivo. Furthermore, 48 h 
after the injection, ESTA-lip accumulation in the tumor 
parenchyma was increased markedly (Fig. 2D), suggesting 
that enhanced tumor vasculature targeting may facilitate 
subsequent extravasation of the liposomes into tumor 
parenchyma. Interestingly, the appearance of speckled 
patterns obtained from these experiments was similar to 
that of ESTA alone [14]. This speckled pattern might be 
due to either intracellular vesicle localization or simply 
a  reflection  of  clustered  and  discontinuous  E-selectin 
expression pattern on the cell surface [15]. Several studies 
suggest that E-selectin internalizes and undergoes a 
recycling following membrane sorting. In addition, our 
3-D confocal imaging analysis of E-selectin expressing 
endothelial cells demonstrated intracellular localization of 
ESTA, suggesting internalization of ESTA (unpublished). 
Although binding kinetics were not measured, 50% of 
the coverage of the liposomes containing 1.1 % amine-
PEG with ESTA was sufficient to produce high-retention 
kinetics (Fig. 2B and C). In this study, we formulated the 
liposomes to contain 1.1% of amino-PEG, although the 
ratio can be modified up to 5% to further enhance the 
amounts  of  ESTA  bioconjugation  to  increase  binding 
specificity and affinity.
Pharmacokinetics of EstA-lip
Pharmacokinetics of the liposomes was then analyzed 
by taking whole blood at different time points after a 
single intravenous bolus administration of the ESTA-lip- 
Rhodamine or NH2-PEG-lip into 10 weeks old FBV mice. 
The fluorescence intensity originated from Rhodamine in 
the plasma of the treated mice over the untreated mice 
was assessed. Following a one compartmental model, 
the pharmacokinetics parameters were determined. There 
was  no  significant  difference  in  the  initial  volume  of 
distribution between two types of liposomes (4.2 ± 0.2 
Kel (hr-1)a T1/2 (hr)b Vd (mL)c AUC (mg.hr/mL)e CL (mL/hr)d
PEG-lip 0.030 ± 0.004 24 ± 4 4.2 ± 0.2 24848 ± 4897 0.12 ± 0.03
ESTA- 
lip 0.022 ± 0.004 32 ± 7 4.2 ± 0.4 33349 ± 4236 0.09 ± 0.01
a The elimination rate constant (kel) was obtained from the linear regression plot of the log Cp vs time curves. bThe half life (T1/2) was calculated 
using the formula: T(1/2)= 0.693/kel. cVolume of distribution (Vd) was calculated using the formula: Vd= dose/ Co , where Co is the extrapolated 
initial concentration. dArea under the curve was calculated from the formula: AUC= Co/Kel, eThe Clearance (CL) was calculated using the formula: 
CL= Kel x VdOncotarget 2011; 2:  298 - 304 302 www.impactjournals.com/oncotarget
mL for NH2-PEG-lip vs. 4.2 ± 0.4 mL for ESTA-lip). On 
the other hand, ESTA conjugation resulted in a decrease in 
the clearance rate (CL) (0.12 ± 0.03 μg.h for NH2-PEGlip 
vs. 0.09 ± 0.01 μg.h for ESTA-lip), and in turn led to an 
increase of the area under the curve (AUC) (24848 ± 4897 
µg.h/mL for NH2-PEG-lip vs. 33349± 4236 µg.h/mL for 
ESTA-lip) and slight extension of the circulation half-life 
(T1/2) (23 ± 4 h for the NH2-PEG-lip vs. 32 ± 7 h for ESTA-
lip). This data supported that the presence of thioaptamer 
ligands (ESTA) on the surface of stealth liposomes does 
not cause a reduction of the bioavailability. 
dIscUssION
Many  targeted  delivery  systems  have  been 
developed using different types of nanoparticles and 
ligands for both imaging and drug delivery [16-20]. While 
antibodies have been the mainstay for active targeting, the 
use of antibodies or peptide based ligands for nanocarriers 
remains a challenge [21-23]. For example, it is difficult 
to control the orientation of antibody on the surface of 
nanocarriers by chemical conjugation since there are a 
number of reactive groups within a molecule, and such 
random conjugation may lead to unexpected off-target 
effects  as  well  as  poor  targeting  performance.  More 
importantly, antibody conjugation to carriers causes 
a reduction in serum half-life due to the clearance by 
phagocytes in tissues and peripheral circulation [21-23]. 
The use of humanized or fragmented antibodies may 
address this issue; however, such strategies appear to be 
neither cost effective nor practical. For this reason, we 
selected thioaptamer. Aptamers are structurally distinct 
RNA and DNA oligonucleotides that have been shown 
to mimic protein-binding molecules, and yet exhibit high 
(nM  to  pM)  binding  affinity  and  selectivity  [24],  and 
can be an attractive alternative over antibody or peptide 
ligands based on their biological and chemical properties 
including, 1) small size, 2) high affinity binding, 3) low 
toxicity and immunogenicity, 4) simple and inexpensive 
chemical  synthesis  and  modification  process,  and  5) 
ability to define the orientation during conjugation[25]. 
Among  the  aptamers  that  have  been  identified  so  far, 
two  DNA  classes  of  aptamers  against  prostate-specific 
membrane antigen (PSMA) [26] and nucleolin [27] have 
been conjugated to nanoparticles, for the cancer cell 
specific targeted drug delivery, and demonstrated effective 
delivery of chemotherapeutic agent specifically to cancer 
cells [28, 29].
As expected, ESTA conjugation to stealth liposome 
did not compromise the T1/2, and rather caused a slight 
extension of the T1/2. The mechanisms underlying extended 
T1/2 of ESTA-lip is not clear. One possible explanation 
might be that the negative surface charge of ESTA-lip (-7.5 
± 0.9 mV) attributed from substitution of the surface amino 
groups might have reduced the interaction of ESTA-lip to 
the negatively charged immune cell surfaces. Nevertheless, 
our  finding  points  to  the  direction  that  thioaptamer 
conjugation is not likely to cause a loss of stealth effect 
of nanoparticles. Active targeting of stealth liposome may 
allow for a reduction in the dose of administration and/or 
decrease toxicity for the chemotherapeutics. In this study, 
we  focused  on  E-selectin  targeted  thioaptamer  (ESTA) 
and stealth liposomes, however, the combinations of type 
of aptamer and nanoparticles are virtually unlimited for 
the development of desirable nanoparticles.
MAtErIAL ANd MEtHOds
synthesis of cy3-labeled carboxylated EstA
ESTA  (5’-CGCTCGGA*TCGA*TA*A*GCTT
CGA*TCCCA*CTCTCCCGTTCA*CTTCTCCTCA
*C  GTCA*CGGA*TCCTCTA*GA*GCA*CTG-3’,  * 
indicates thioation) was chemically synthesized in a DNA 
synthesizer (Expedite 8909, Applied Biosystems) using 
the standard phosphoramidite chemistry as described 
previously [30]. The 5’ end of the ESTA was coupled with 
Cy3  phosphoramidite  with  the  MMT  protective  group 
remaining  and  followed  by  the  addition  of  5’-carboxy 
modifier-C10  containing  N-hydroxy  succinimide 
ester  protective  group.  After  functionalization,  ESTA 
was cleaved from the bead support and the protecting 
groups  were  removed  with  0.4M  methanolic  NaOH  at 
room temperature for 24-36 hr. The resultant ESTA was 
further purified and the concentration of the ESTA was 
determined by measuring the absorbance at 260 nm with a 
UV spectrophotometer. 
Preparation of EstA conjugated liposome 
(EstA-lip)
Amino-PEG liposomes were made with a lipid 
mixture (50 mM) consisting of DPPC, cholesterol, and 
DSPE-PEG (2000) Amine, in a 58.9: 40: 1.1 molar ratio, 
dissolved in ethanol and then hydrated with either; (1) 10 
mM phosphate buffered saline to prepare empty liposomes 
or (2) 1 mM FITC solution for in vitro studies. This was 
then  sequentially  extruded  using  a  Lipex  thermoline 
extruder to prepare liposomes of approximately 100 
nm.  The  FITC-liposomes  were  diafiltered  through  500 
kDa molecular weight cut-off membranes to remove un-
encapsulated dye. Rhodamine tagged liposomes used 
for in vivo studies were extruded as above. DPPC: Chol: 
DSPE-PEG (2000) amine : Rhodamine-DHPE at 58.8: 
40: 1.1 : 0.1 molar ratio were used. Carboxylated Cy3-
labeled or unlabeled ESTA was conjugated to amino PEG 
liposomes by using carbodiimide chemistry with EDC 
and sulfo-NHS. Free ESTA was removed by dialysis. Oncotarget 2011; 2:  298 - 304 303 www.impactjournals.com/oncotarget
characterization of EstA-lips
The size and zeta potential of the ESTA conjugated 
liposome were measured using a ZetaPals instrument 
(Brookhaven Instruments). 2µl of liposomes were added 
to 1.4 mL of 10mM phosphate buffer (pH 7.3) and the 
analysis was conducted at room temperature (23°C) in 
triplicates.  To  quantify  the  concentration  of  the  ESTA 
on the liposomes, Cy3 fluorescence from ESTA-lip was 
measured and compared with ESTA standard curve. Fourier 
transform infrared spectroscopy (FTIR) was preformed to 
assess the attachment of ESTA on the liposomes. Samples 
were diluted in de-ionized water and FTIR was preformed 
on a Nicolet 6700 (Thermo Scientific, Waltham, MA). A 
2µL drop from each sample was placed on the diamond 
crystal and subjected to vacuum. Using a smart diamond 
crystal attenuated total reflection (ATR) accessory each 
sample was run for 150 scans at a resolution of 4 wave 
numbers.
Induction of E-selectin expression in HUVEc 
cells
To induce E-selectin expression, the cells were 
stimulated with TNF-α  (10ng/ml)  for  2  to  4  h.  To 
determine E-selectin expression on the endothelial cell 
surface, the cells were dissociated with 5 mM EDTA and 
then incubated with FITC labeled E-selectin antibody 
(Pharmingen). As a negative control, the same amount 
of normal IgG was used. The surface fluorescence was 
measured  by  a  FACS  Caliber.  The  experiments  were 
repeated at least three times and data represent an average 
value. 
EstA-lip binding to E-selectin expressing 
endothelial cells
100  nM  of  Cy3-ESTA  conjugated  liposomes 
encapsulating  FITC  (Cy3-ESTA-lip-FITC)  were 
incubated  with  HUVEC  that  were  treated  or  untreated 
with TNF-α for 2 hours at 37ºC. As a negative control, 
NH2 PEG liposomes encapsulating FITC (NH2-PEG-lip) 
were used. Following 3 hours incubation, the cells were 
briefly washed with tissue culture media to remove the 
unbound liposomes and then incubated overnight. The 
cells were fixed with 4% paraformaldehyde, and the nuclei 
were counterstained with 1.0 µg/ml Hoechst 33342. The 
fluorescent signals were detected using TE2000-E, Nikon 
fluorescent microscope (x600 magnification) to determine 
the binding to the cells. All images were acquired under 
the same exposure conditions for the comparison of 
liposome binding to the cells.
In vivo carcinoma mouse model
5-week old female athymic nu/nu nude mice 
(Charles  River)  were  maintained  in  a  VAF-barrier 
facility and all animal procedures were performed in 
accordance with the regulations in the Institutional 
Animal  Care  and  Use  Committee  at  the  University  of 
Texas Health Science Center at Houston. An orthotopic 
breast tumor was established as previously reported 
with minor modification. When tumors became palpable 
(approx.  200-300  mm3),  either  encapsulated  ESTA-lip-
rhodamine or NH2-PEG-lip (3 mg of total lipid in 100 
µl  of  saline)  was  intravenously  injected  into  mice  via 
tail vein (n=3 per group). One day after the injection, the 
tumors were harvested and immediately mounted in OCT 
media for subsequent histological analysis. To examine 
tumor localization of liposomes, the frozen tissues were 
sectioned (8 µm thickness) and analyzed by fluorescent 
microscope. The frozen sections were also immunostained 
as previously reported [14]. 
Pharmacokinetics of liposomes
Following a single intravenous bolus administration 
of  the  ESTA-Lip-Rhodamine  or  NH2-PEG-Lip  (3  mg 
of total lipid in 100 µl of saline) into 10 weeks old FBV 
mice (n=3-4), whole blood was collected at different time 
points  by  cardiac  puncture.  The  fluorescence  intensity 
in the plasma (50 µl) was measured using a fluorimeter 
at  544/594  nm  (excitation/emission  wavelengths)  to 
determine the pharmacokinetics parameters of each 
liposome. Plasma samples were also collected from 
untreated mice as a baseline.
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